pituitary apoplexy/testosterone

Lyen an sove nan clipboard la

AtikEsè klinikPatant

Chwazi kalite sòt

14 rezilta yo

RECURRENT PITUITARY APOPLEXY IN AN ADENOMA WITH SWITCHING PHENOTYPES

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Objective: To describe an unusual presentation of a patient with recurrent pituitary apoplexy of an adenoma that switched phenotypes from a nonfunctioning, or silent gonadotroph adenoma (SGA), to a silent corticotroph adenoma (SCA). We

Pituitary apoplexy developed in a patient with androgen insensitivity syndrome.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

At the age of 18, our patient was diagnosed as complete androgen insensitivity syndrome(AIS) based on androgen receptor studies in cultured genital skin fibroblasts. Compatible with this diagnosis, both testosterone and LH levels in her plasma were elevated as compared to levels in normal females.

Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The syndrome of pituitary apoplexy has been reported to occur after the administration of several different medications. We report a case in which pituitary apoplexy developed shortly after the administration of leuprolide in a patient with prostate cancer. Leuprolide is a potent gonadotrophin

Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Gonadotrophin-releasing hormone agonists (GnRHAs) are used in many clinical conditions, particularly prostate cancer. There have been a few case reports of apoplexy from a previously undiagnosed pituitary tumour, occurring within hours to days of initiation of GnRHA therapy. We report a case of

Pituitary apoplexy induced by gonadotropin-releasing hormone agonist administration: a rare complication of prostate cancer treatment

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Summary: Gonadotropin-releasing hormone (GnRH) agonists, currently used in the treatment of advanced prostate cancer, have been described as a rare cause of pituitary apoplexy, a potentially life-threatening clinical condition. We report

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Pituitary apoplexy represents an uncommon endocrine emergency with potentially life-threatening consequences. Drug-induced pituitary apoplexy is a rare but important consideration when evaluating patients with this presentation. We describe an unusual case of a patient with a known pituitary

Uncontrolled diabetes as a rare presenting cause of pituitary apoplexy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Pituitary apoplexy is a rare endocrine emergency. The extent to which hyperglycaemia is a contributory risk factor in the precipitation of pituitary apoplexy is not known. A 38-year-old man with poorly controlled diabetes presented to the emergency department with sudden onset of nausea and headache

Pituitary apoplexy: retrospective review of 30 patients--is surgical intervention always necessary?

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The objective of this article is to review clinical outcomes in patients presenting with pituitary apoplexy and compare the results of conservative and surgical management. It took the form of a retrospective review of 30 patients (23M, 7F; age range: 17-86 years) with pituitary apoplexy diagnosed

A retrospective analysis of pituitary apoplexy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Thirty-seven patients with pituitary apoplexy were analyzed with an emphasis on clinical presentation and visual outcome. Their mean age was 56.6 years, with a male to female ratio of 2:1. Presenting symptoms included headache (95%), vomiting (69%), ocular paresis (78%), and reduction in visual

Classical pituitary apoplexy: clinical features, management and outcome.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE The term classical pituitary apoplexy describes a clinical syndrome characterized by sudden headache, vomiting, visual impairment and meningismus caused by the rapid enlargement of a pituitary adenoma usually due to haemorrhagic infarction of the tumour. Most published reports looking at

Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Treatment of prostatic cancer with GnRH agonist is a medical alternative to surgical castration, although hyperstimulation of the tumor can occur. We describe an unusual unwanted effect of such a treatment which unmasked a clinically silent gonadotroph adenoma. A 62-year-old man developed after the

Prepubescent pituitary null cell macroadenoma with silent macroscopic apoplexy: case report.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Secreting pituitary adenomas have marked prevalence in pediatric adenomas. We described a case of an 11-year-old boy with pituitary null cell macroadenoma with silent macroscopic pituitary apoplexy. The patient was admitted with bitemporal hemianopsia and a gradual deterioration of visual acuity. An

Subarachnoid hemorrhage with normal cerebral angiography: a prospective study on sellar abnormalities and pituitary function.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Ten consecutive patients with subarachnoid hemorrhage (SAH) of unknown cause were examined for sellar abnormalities and pituitary dysfunction. The diagnosis of SAH rested on a typical history and the demonstration of blood in the cerebrospinal fluid (computed tomography (CT), lumbar puncture).

Management of Hypopituitarism.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

: Hypopituitarism includes all clinical conditions that result in partial or complete failure of the anterior and posterior lobe of the pituitary gland's ability to secrete hormones. The aim of management is usually to replace the target-hormone of hypothalamo-pituitary-endocrine gland axis

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye